Who are Ovitrelle ( Hcg 250 mcg)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orgovyx, Orilissa, Firmagon, Luveris, Cetrotide, Ovidrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ovitrelle-hcg-250-mcg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ovitrelle ( Hcg 250 mcg) — Competitive Intelligence Brief

Ovitrelle ( Hcg 250 mcg) (Ovitrelle ( Hcg 250 mcg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin; recombinant human chorionic gonadotropin (rhCG). Area: Reproductive Medicine / Fertility.

marketed Gonadotropin; recombinant human chorionic gonadotropin (rhCG) Luteinizing hormone receptor (LH receptor) Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Ovitrelle ( Hcg 250 mcg) (Ovitrelle ( Hcg 250 mcg)) — Fundacion Clinic per a la Recerca Biomédica. Ovitrelle is a recombinant human chorionic gonadotropin (hCG) that mimics the natural hormone to trigger final oocyte maturation and ovulation in assisted reproductive cycles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ovitrelle ( Hcg 250 mcg) TARGET	Ovitrelle ( Hcg 250 mcg)	Fundacion Clinic per a la Recerca Biomédica	marketed	Gonadotropin; recombinant human chorionic gonadotropin (rhCG)	Luteinizing hormone receptor (LH receptor)
Orgovyx	relugolix	MYOVANT SCIENCES	marketed	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	Gonadotropin-releasing hormone receptor	2020-01-01
Orilissa	ELAGOLIX	AbbVie	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2018-01-01
Firmagon	degarelix	Ferring	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2008-01-01
Luveris	r-hLH	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2004-01-01
Cetrotide	CETRORELIX	Merck KGaA	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2000-01-01
Ovidrel	CHORIOGONADOTROPIN ALFA	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-02-25 — Orgovyx · 10350170 · US
2037-09-29 — Orgovyx · 10449191 · US
2037-09-29 — Orgovyx · 11583526 · US
2037-09-29 — Orgovyx · 11033551 · US
2037-09-29 — Orgovyx · 10786501 · US

Sponsor landscape (Gonadotropin; recombinant human chorionic gonadotropin (rhCG) class)

Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ovitrelle ( Hcg 250 mcg) — Competitive Intelligence Brief. https://druglandscape.com/ci/ovitrelle-hcg-250-mcg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab